LGI2 Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA520493-Each-of-1 | In Stock | ₹ 45,968.50 |
PIPA520493 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 45,968.50
GST (18%): ₹ 8,274.33
Total Price: ₹ 54,242.83
Antigen
LGI2
Classification
Polyclonal
Conjugate
Unconjugated
Gene
Lgi2
Gene Alias
Kiaa1916; leucine rich repeat LGI family member 2; leucine-rich glioma-inactivated protein 2; Leucine-rich repeat LGI family member 2; leucine-rich repeat LGI family, member 2; leucine-rich, glioma inactivated 2; LGI1-like protein 2; Lgi2; LGIL2; mKIAA1916
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
246316, 55203
Content And Storage
Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C
Form
Liquid
Applications
Immunohistochemistry, Western Blot
Concentration
1 mg/mL
Formulation
PBS with 0.02% sodium azide
Gene Accession No.
Q8K4Z0, Q8N0V4
Gene Symbols
Lgi2
Immunogen
a 10 amino acid peptide from near the center of human LGI2.
Quantity
100 μg
Primary or Secondary
Primary
Target Species
Human, Mouse
Product Type
Antibody
Isotype
IgG
Related Products
Description
- A suggested positive control is mouse liver tissue lysate
- PA5-20493 can be used with blocking peptide PEP-0613
- The leucine-rich, glioma inactivated gene 2 (LGI2) is a member of the LGI family in which LGI1 is the exemplar
- The LGI family consists of four of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors
- LGI1 has been identified as a candidate tumor suppressor gene for glioma and plays a role in autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms
- Despite its high homology with LGI1 and similar pattern of expression, mutations in LGI2 have not been found to be associated with ADTLE.